Posted by PeterMartin on December 21, 2018, at 0:38:32
Glaxo has made a business decision to no longr make Requip aside from a few hight dose XL versions. Heads up for anyone who takes it.
The Food and Drug Administration (FDA) has posted a discontinuation notice for Requip (ropinirole HCl; GlaxoSmithKline) tablets and certain Requip XL (ropinirole HCl; GlaxoSmithKline) extended-release tablets.
Requip and Requip XL are non-ergot dopamine agonists indicated for the treatment of Parkinson's disease.
The affected products include Requip 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg, and 5mg strength tablets in 100-count bottles, and Requip XL 2mg strength tablets in 30-count bottles. The anticipated final dates of availability to patients are as follows:
Requip 0.25mg (NDC 0007-4890-20): April 2019
Requip 0.5mg (NDC 0007-4891-20): May 2019
Requip 1mg (NDC 0007-4892-20): January 2019
Requip 2mg (NDC 0007-4893-20): January 2019
Requip 3mg (NDC 0007-4895-20): April 2019
Requip 4mg (NDC 0007-4896-20): May 2019
Requip 5mg (NDC 0007-4894-20): March 2019
Requip XL 2mg (NDC 0007-4885-13): March 2019
The discontinuation of these products was a business decision, according to the FDA notice. Requip XL is still available as 4mg, 6mg, 8mg, and 12mg extended-release tablets.
poster:PeterMartin
thread:1102548
URL: http://www.dr-bob.org/babble/20181024/msgs/1102548.html